Learn About Heart Failure with Preserved Ejection Fraction (HFpEF)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Heart Failure with Preserved Ejection Fraction (HFpEF) Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the Latest Advances for Heart Failure with Preserved Ejection Fraction (HFpEF)?
Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report.
Summary: Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report.
Progress in the management of patients with diabetes and chronic kidney disease.
Summary: Progress in the management of patients with diabetes and chronic kidney disease.
Tired of the same old research?
Check Latest Advances
New concepts in heart failure with preserved ejection fraction and hypertension.
Summary: New concepts in heart failure with preserved ejection fraction and hypertension.
What are the latest Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials?
Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction Before and After Ablation of Atrial Fibrillation
Summary: In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after AF ablation.
Match to trials
Find the right clinical trials for you in under a minute
Get started
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
Summary: This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that increase perfusion and fatty acid oxidation [Potassium Nitrate (KNO3)], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure w...